Pyxis Oncology (PYXS) News Today → He called Apple at $1.49 and now he says: “Buy these 6 AI stocks.” (From InvestorPlace) (Ad) Free PYXS Stock Alerts $4.15 -0.02 (-0.48%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 4:16 AM | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Pyxis Oncology (NASDAQ:PYXS)May 18 at 1:45 AM | americanbankingnews.comWilliam Blair Weighs in on Pyxis Oncology, Inc.'s Q2 2024 Earnings (NASDAQ:PYXS)May 17 at 7:10 AM | marketbeat.comQ2 2024 Earnings Estimate for Pyxis Oncology, Inc. (NASDAQ:PYXS) Issued By William BlairPyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Stock analysts at William Blair cut their Q2 2024 earnings per share estimates for Pyxis Oncology in a report released on Tuesday, May 14th. William Blair analyst A. Hsieh now forecasts that the company will post earnings of ($0.34) per share forMay 16 at 2:45 PM | markets.businessinsider.comBuy Rating Affirmed for Pyxis Oncology on Strong Financials and Promising Clinical ProgressMay 16 at 8:41 AM | marketbeat.comPyxis Oncology (NASDAQ:PYXS) Rating Reiterated by HC WainwrightHC Wainwright reissued a "buy" rating and set a $7.00 price target on shares of Pyxis Oncology in a research report on Thursday.May 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pyxis Oncology on Robust Clinical Pipeline and Solid FinancialsMay 15, 2024 | marketbeat.comPyxis Oncology (NASDAQ:PYXS) Posts Earnings Results, Beats Expectations By $0.19 EPSPyxis Oncology (NASDAQ:PYXS - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.19. The firm had revenue of $16.15 million during the quarter, compared to analysts' expectations of $4.25 million.May 14, 2024 | globenewswire.comPyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024May 13, 2024 | marketbeat.comPyxis Oncology, Inc. (NASDAQ:PYXS) Sees Significant Decline in Short InterestPyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) saw a significant decrease in short interest in April. As of April 30th, there was short interest totalling 1,850,000 shares, a decrease of 16.3% from the April 15th total of 2,210,000 shares. Approximately 4.0% of the shares of the stock are sold short. Based on an average daily volume of 749,400 shares, the short-interest ratio is presently 2.5 days.May 9, 2024 | globenewswire.comPyxis Oncology to Present at the RBC Capital Markets Global Healthcare ConferenceMay 9, 2024 | americanbankingnews.comJefferies Financial Group Reiterates Buy Rating for Pyxis Oncology (NASDAQ:PYXS)April 30, 2024 | marketbeat.comabrdn plc Makes New Investment in Pyxis Oncology, Inc. (NASDAQ:PYXS)abrdn plc acquired a new stake in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 708,303 shares of the company's stock, valued at approximately $1,275,000. abrdn plc owned approximately 1.60%April 28, 2024 | marketbeat.comPyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Down 18.1% in AprilPyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) was the target of a large drop in short interest in April. As of April 15th, there was short interest totalling 2,210,000 shares, a drop of 18.1% from the March 31st total of 2,700,000 shares. Approximately 4.8% of the company's stock are short sold. Based on an average trading volume of 909,000 shares, the days-to-cover ratio is currently 2.4 days.April 14, 2024 | finance.yahoo.comPYXS Oct 2024 10.000 callApril 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pyxis Oncology as PYX-201 Showcases Promising Preclinical Data and Broad Therapeutic PotentialApril 10, 2024 | marketbeat.comPyxis Oncology (NASDAQ:PYXS) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $7.00 price objective on shares of Pyxis Oncology in a research report on Wednesday.April 3, 2024 | msn.comWhy Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionMarch 28, 2024 | globenewswire.comPyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Spectral AI (MDAI) and Pyxis Oncology (PYXS)March 28, 2024 | seekingalpha.comPyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The WaitMarch 27, 2024 | investorplace.com3 Biotech Stocks to Buy on the Dip: March 2024March 27, 2024 | msn.comPyxis Oncology gets $8M payment for sale pf royalty rightsMarch 27, 2024 | globenewswire.comPyxis Oncology Obtains $8 Million Payment for the Sale of Royalty RightsMarch 25, 2024 | markets.businessinsider.comOptimistic Buy Rating for Pyxis Oncology’s PYX-201 Based on Strong Safety Profile and Promising Therapeutic PotentialMarch 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pyxis Oncology on Strong Clinical and Financial ProspectsMarch 22, 2024 | marketbeat.comPyxis Oncology (NASDAQ:PYXS) Receives "Outperform" Rating from Royal Bank of CanadaRoyal Bank of Canada reaffirmed an "outperform" rating and set a $7.00 target price on shares of Pyxis Oncology in a report on Friday.March 22, 2024 | marketbeat.comPyxis Oncology (NASDAQ:PYXS) Given New $7.00 Price Target at HC WainwrightHC Wainwright increased their price target on shares of Pyxis Oncology from $4.00 to $7.00 and gave the stock a "buy" rating in a research note on Friday.March 22, 2024 | markets.businessinsider.comBuy Rating Affirmed: Pyxis Oncology’s Financial Health and Promising Drug Candidate PYX-201 Bolster OptimismMarch 21, 2024 | marketwatch.comPyxis Oncology Shares Fall 10% After Apparent Delay in ResultsMarch 21, 2024 | investorplace.comPYXS Stock Earnings: Pyxis Oncology Beats EPS for Q4 2023March 21, 2024 | benzinga.comPyxis Oncology: Q4 Earnings InsightsMarch 21, 2024 | finance.yahoo.comPyxis Oncology Inc (PYXS) Reports Encouraging Clinical Progress Amid Financial ChallengesMarch 21, 2024 | marketbeat.comPyxis Oncology (PYXS) to Release Quarterly Earnings on FridayPyxis Oncology (NASDAQ:PYXS) will be releasing earnings on Friday, March 22, Yahoo Finance reports.March 21, 2024 | globenewswire.comPyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023March 19, 2024 | investorplace.comFrom Six Figures to Seven: 3 Biotech Stocks Set to Make MillionairesMarch 19, 2024 | markets.businessinsider.comPyxis Oncology (PYXS) Receives a Buy from Leerink PartnersMarch 17, 2024 | finance.yahoo.comPYXS Apr 2024 10.000 callMarch 17, 2024 | finance.yahoo.comPYXS Apr 2024 7.500 putMarch 15, 2024 | finance.yahoo.comPYXS Jul 2024 7.500 callMarch 13, 2024 | marketbeat.com326,810 Shares in Pyxis Oncology, Inc. (NASDAQ:PYXS) Acquired by Decheng Capital Management III Cayman LLCDecheng Capital Management III Cayman LLC purchased a new position in Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 326,810 shares ofMarch 13, 2024 | globenewswire.comPyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFAMarch 7, 2024 | globenewswire.comPyxis Oncology to Present at Leerink Global Biopharma Conference 2024March 5, 2024 | globenewswire.comPyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual MeetingFebruary 27, 2024 | marketwatch.comPyxis Oncology Shares Up 21% in Premarket Trading on $50M FundraiseFebruary 27, 2024 | finance.yahoo.comPyxis Oncology Announces $50 Million Private PlacementFebruary 23, 2024 | benzinga.comPyxis Oncology Stock (NASDAQ:PYXS) Dividends: History, Yield and DatesFebruary 23, 2024 | benzinga.comPyxis Oncology Stock (NASDAQ:PYXS), Analyst Ratings, Price Targets, PredictionsFebruary 22, 2024 | investorplace.com3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024February 17, 2024 | marketbeat.comPyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Buy" from AnalystsPyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) has earned an average recommendation of "Buy" from the eight ratings firms that are presently covering the firm, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy rating. The average 1 year price objective among aFebruary 9, 2024 | markets.businessinsider.comBuy Rating for Pyxis Oncology: Advancing ADC Innovation and Immuno-Oncology Pipeline Get Pyxis Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter. Email Address Buy this small stock before coming AI Tidal Wave (Ad)The internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture. Get the name and ticker symbol for free - just click here. PYXS Media Mentions By Week PYXS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PYXS News Sentiment▼0.560.42▲Average Medical News Sentiment PYXS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PYXS Articles This Week▼141▲PYXS Articles Average Week Get Pyxis Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALDX News OMER News TSVT News GTHX News FHTX News DSGN News PBYI News IMMP News AKBA News GBIO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PYXS) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubNext President (Not Trump. Not Biden.)The Freeport SocietyCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pyxis Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
